Status: Recruiting
Clinical Trial of Infusion of Activated NK Cells for the Treatment of Sarcomas
This is an exploratory therapeutic study (according to the terminology of the "ICH Harmonised Tripartite Guideline Topic E8. General Considerations for Clinical Trials". EMEA, March 1998. CPMP/ICH/291/95), open-label, non-randomized, multicenter study. It is considered phase I/II since the safety and efficacy of the infusion of allogeneic haploidentical NK cells in combination with chemotherapy and/or radiotherapy in the treatment of pediatric, adolescent and young adult patients with refractory sarcoma will be sought.
Participants needed: 10
Trial details
Age: Up to 30Biological sex: AllType: InterventionalSponsor: Antonio Pérez MartínezUpdated: Jul 21, 2023Locations: 1
Eligibility criteria
Patients aged between 0 and 30 years diagnosed with malignant sarcoma, who at th... [+8]
Patients with a history of poor therapeutic compliance. [+8]